



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/130981/>

Version: Accepted Version

---

**Article:**

Bewley, M.A., Budd, R.C., Ryan, E. et al. (2018) Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease is Enhanced by Nrf2 Agonists. *American Journal of Respiratory and Critical Care Medicine*, 198 (6). ISSN: 1073-449X

<https://doi.org/10.1164/rccm.201705-0903OC>

---

© 2018 American Thoracic Society. This is an author produced version of a paper subsequently published in *American Journal of Respiratory and Critical Care Medicine*. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

1 **Opsonic phagocytosis in chronic obstructive pulmonary disease is enhanced by**  
2 **Nrf2 agonists.**

3 Martin A. Bewley<sup>1</sup>, Richard C Budd<sup>1,2</sup>, Eilise Ryan<sup>3</sup>, Joby Cole<sup>1,2</sup>, Paul Collini<sup>1,2</sup>, J  
4 Marshall<sup>3</sup>, Umme Kolsum<sup>4</sup>, Gussie Beech<sup>4</sup>, Richard D. Emes<sup>5</sup>, Irina Tcherniaeva<sup>6</sup>,  
5 Guy A. M. Berbers<sup>6</sup>, Sarah R. Walmsley<sup>3</sup>, Gavin Donaldson<sup>7</sup>, Jadwiga A. Wedzicha<sup>7</sup>,  
6 Iain Kilty<sup>8</sup>, William Rumsey<sup>9</sup>, Yolanda Sanchez<sup>9</sup>, Christopher E. Brightling<sup>10</sup>, Louise  
7 E. Donnelly<sup>7</sup>, Peter J. Barnes<sup>7</sup>, Dave Singh<sup>3</sup>, Moira K.B. Whyte<sup>3</sup> and David H.  
8 Dockrell<sup>11\*</sup> on behalf of COPDMAP.

9  
10 <sup>1</sup> Department of Infection Immunity and Cardiovascular Disease and The Florey  
11 Institute for Host-Pathogen Interactions, University of Sheffield Medical School, UK,  
12 <sup>2</sup>Sheffield Teaching Hospitals, <sup>3</sup>Department of Respiratory Medicine and MRC  
13 Centre for Inflammation Research, University of Edinburgh, <sup>4</sup>Medicine Evaluation  
14 Unit, University of Manchester and University Hospital of South Manchester, <sup>5</sup>  
15 School of Veterinary Medicine and Science and Advanced Data Analysis Centre,  
16 University of Nottingham, UK, <sup>6</sup>Center for Infectious Disease Control (CIb), National  
17 Institute for Public Health and the Environment (RIVM), the Netherlands, <sup>7</sup>National  
18 Heart and Lung Institute, University of London Imperial College, UK, <sup>8</sup> Pfizer Inc,  
19 Cambridge, Massachusetts, <sup>9</sup> Stress and Repair Discovery Performance Unit,  
20 Respiratory Therapy Area, GSK, King of Prussia, USA <sup>10</sup>Institute for Lung Health,  
21 University of Leicester, UK, <sup>11</sup>Department of Infection Medicine and MRC Centre  
22 for Inflammation Research, University of Edinburgh. **Corresponding Author:** David  
23 H. Dockrell, The MRC/University of Edinburgh Centre for Inflammation Research,  
24 47 Little France Crescent, Edinburgh, Edinburgh EH16 4TJ UK Phone: +44 (0) 131  
25 242 658 Fax: +44 (0) 131 242 6578 email: [david.dockrell@ed.ac.uk](mailto:david.dockrell@ed.ac.uk).

26  
27 **Author contributions:** MAB, ER performed killing assays, flow cytometry,  
28 microscopy and collected data. MAB and JC produced figures. RCB, ER, UK, PC and  
29 DS co-ordinated and performed bronchoscopies to obtain patient samples. RCB, UK  
30 and GB performed clinical phenotyping. JC, ER and RE performed transcriptomic  
31 analysis. IT and GB provided multiplex immunoassays on BAL, WR and YS  
32 provided compounds and input into experimental design. GD, JAW, SRW, IK, LED,  
33 PJB, DS and CEB co-ordinated collection of the COPD patient cohort and controls,  
34 shared expertise in assays and provided reagents. MAB, MKBW and DHD designed  
35 and conceived the experiments. MAB, MKW and DHD wrote the manuscript with  
36 input from all other authors.

37  
38 This research was funded by the Medical Research Council (MRC) and the  
39 Association of the British Pharmaceutical Industry (ABPI) though support for the  
40 COPD-MAP consortium.

41  
42 **Running title:** Nrf2 enhances opsonic phagocytosis in COPD.

43 **Descriptor Number:** 10.9 Pathogen/Host cell interactions (9.13 COPD pathogenesis,  
44 9.14 COPD pharmacological treatment)

45 **Abstract 249 Total word count: 3694**

46 **At a glance summary:**

47 **Scientific Knowledge on the Subject:** COPD macrophages have defective  
48 phagocytosis but the mechanism and clinical relevance remain unknown.

1 **What This Study Adds to the Field:** COPD alveolar macrophages (AM) have a  
2 specific defect in opsonic phagocytosis which correlates with clinical phenotype.  
3 COPD AM fail to engage an anti-oxidant transcriptional module following exposure  
4 to opsonized bacteria. Agonists of a key transcriptional regulator of anti-oxidant host  
5 defense, Nrf2, reverse the opsonic phagocytosis defect in COPD and offer a potential  
6 therapeutic approach to correct the defect.

7  
8 **Footnote:**

9 Presented in part as “COPD alveolar macrophages have a defect in opsonic  
10 phagocytosis of serotype 14 *Streptococcus pneumoniae*”. M.Bewley, R.Budd,  
11 D.Singh, P.J. Barnes, L.E. Donnelly, D.H.Dockrell and M.K.Whyte. American  
12 Thoracic Society International Conference San Diego May 18<sup>th</sup>, 2014. Am J. Respir  
13 Crit Care Med 189:2014; A1011

14  
15 This article has an online data supplement, which is accessible from this issue's table  
16 of content online at [www.atsjournals.org](http://www.atsjournals.org)

17

1 **Abstract**

2 **Rationale:** Previous studies have identified defects in bacterial phagocytosis by  
3 alveolar macrophages (AM) in patients with chronic obstructive pulmonary disease  
4 (COPD) but the mechanisms and clinical consequences remain incompletely defined.

5 **Objectives:** To examine the effect of COPD on AM phagocytic responses and  
6 identify the mechanisms, clinical consequences and potential for therapeutic  
7 manipulation of these defects.

8 **Methods:** We isolated alveolar macrophages (AM) and monocyte-derived  
9 macrophages (MDM) from a cohort of COPD patients and controls within the MRC  
10 COPD-MAP consortium and measured phagocytosis of bacteria in relation to opsonic  
11 conditions and clinical features.

12 **Measurements and Main Results:** COPD AM and MDM have impaired  
13 phagocytosis of *S. pneumoniae*. COPD AM have a selective defect in uptake of  
14 opsonized bacteria, despite the presence of anti-pneumococcal antibodies in  
15 bronchoalveolar lavage, not observed in MDM or healthy donor's AM. AM defects in  
16 phagocytosis in COPD are significantly associated with exacerbation frequency,  
17 isolation of pathogenic bacteria and health related quality of life scores. Bacterial  
18 binding and initial intracellular killing of opsonized bacteria in COPD AM was not  
19 reduced. COPD AM have reduced transcriptional responses to opsonized bacteria,  
20 including cellular stress responses that include transcriptional modules involving  
21 antioxidant defenses and Nrf2-regulated genes. Agonists of the cytoprotective  
22 transcription factor Nrf2 (sulforaphane and Compound 7) reverse defects in  
23 phagocytosis of *S. pneumoniae* and non-type able *Haemophilus influenzae* by COPD  
24 AM.

25 **Conclusions:** Patients with COPD have clinically relevant defects in opsonic

- 1 phagocytosis by AM, associated with impaired transcriptional responses to cellular
- 2 stress, which are reversed by therapeutic targeting with Nrf2 agonists.

1 **Introduction.**

2

3 Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung  
4 condition characterised by progressive airflow limitation (1, 2). COPD is associated  
5 with increased susceptibility to bacterial airway infection. Exacerbations cause acute  
6 worsening of symptoms, leading to hospitalization (3) and to disease progression (4).  
7 Approximately 50% of exacerbations are due to bacterial infection (5) and, in a long-  
8 term cohort study, the lower airways were chronically colonized with *Streptococcus*  
9 *pneumoniae* in a third of patients (6). Individuals living with COPD are also at  
10 increased risk of community-acquired pneumonia (CAP) with increased mortality,  
11 most often caused by *S. pneumoniae* (7). This suggests COPD leads to an innate  
12 immune defect against *S. pneumoniae* and other bacteria.

13

14 Alveolar macrophages (AM) are the resident phagocytes enabling bacterial clearance  
15 from the lung, but COPD AM demonstrate reduced phagocytosis of *Haemophilus*  
16 *influenzae* and *P. aeruginosa* (8, 9), while COPD monocyte-derived macrophages  
17 (MDM) show impaired phagocytosis of *S. pneumoniae* (10). Bacterial phagocytosis  
18 by macrophages involves both non-opsonic and opsonic pathways (11, 12). Previous  
19 studies of COPD macrophages have examined non-opsonic or complement-mediated  
20 phagocytosis but phagocytosis in the presence of opsonizing antibody has not been  
21 studied in detail. A specific defect in opsonic phagocytosis would be particularly  
22 relevant to capsulated micro-organisms, such as *S. pneumoniae*, which require  
23 opsonization for efficient phagocytosis (13), involving both IgG and complement  
24 present in alveolar fluid (14).

25

1 We investigated mechanisms underlying phagocytic defects in the COPD lung. COPD  
2 Opsonization fails to enhance AM phagocytosis, although it enhances MDM  
3 phagocytosis. The level of AM opsonic phagocytosis was strongly associated with  
4 clinical and microbiological phenotype. AM responses to opsonized *S. pneumoniae*  
5 activated cellular stress transcriptional responses to antioxidant responses, but these  
6 were abrogated in COPD AM. Agonists of the antioxidant transcription factor,  
7 nuclear factor (erythroid-derived2) like 2 (NFE2L2) or Nrf2, a prominent component  
8 of antioxidant transcriptional responses, corrected the defect in AM opsonic  
9 phagocytosis in COPD. Some of the results of these studies have been previously  
10 reported in the form of an abstract (15).

11

1 **Methods**

2 *Macrophage donors:* COPD patients, free from exacerbation, were recruited from the  
3 UK Medical Research Council (MRC) COPD-MAP consortium with written  
4 approved consent, as outlined online.

5

6 *Cells and Infection:* AM were isolated from broncho-alveolar lavage (BAL) as  
7 previously described (13) Cells were >95% AM as assessed by Diff-Quick staining  
8 (Dade Behring) visualised by light microscopy (Leica DMRB 1000). Human MDM  
9 were differentiated for 14 d from peripheral blood mononuclear cells isolated from  
10 donors with written informed consent by Percoll (Sigma) gradient. Cells were  
11 cultured in RPMI (Lonza) supplemented with 10% FCS with low LPS (Lonza). Some  
12 cells were incubated with 10  $\mu$ M of sulforaphane, 0.065  $\mu$ M Compound 7, a selective  
13 inhibitor of the Kelch-like ECH-associated protein 1 (KEAP1) /Nrf-2 interaction  
14 (16), or vehicle control for 16 h before challenge with bacteria.

15

16 *Bacteria:* Serotype 14 *S. pneumoniae* (NCTC11902) represents a serotype commonly  
17 causing infection in COPD (17). Stocks were grown as previously described (18).  
18 Non-typeable *H. influenzae* (NCTC 1269) was cultured as outlined in the online  
19 supplement. Macrophages were infected at a multiplicity of infection (MOI) of 10:1.  
20 *S. pneumoniae* were opsonized for 15 min. with immune serum obtained from  
21 volunteers vaccinated with pneumococcal polysaccharide vaccine, and with detectable  
22 antibody levels against *S. pneumoniae*, prior to macrophage challenge (13). Viable  
23 intracellular bacteria were measured at 4 h post-challenge as a measure of bacterial  
24 internalization using a gentamicin protection assay (GPA) as previously described  
25 (19). For assessment of early *S. pneumoniae* killing, macrophages were challenged for

1 4 h before GPA, while additional wells were placed in media containing 0.75 µg/ml  
2 vancomycin before GPA at the designated time points.

3  
4 *Bacterial binding:* Bacterial binding and internalisation were assessed by fluorescence  
5 microscopy (Leica DMRB 1000) (13). Detailed information can be found in the  
6 online supplement.

7  
8 *Cell surface marker expression.* Cell surface marker expression was measured by  
9 flow cytometry, as described online.

10  
11 *Transcriptomic analysis:* RNA was extracted and hybridized onto the Affymetrix HG-  
12 U133 plus 2.0 Array. Data were analysed in R using affyPML and Limma.  
13 Enrichment analysis of Gene Ontology (GO) terms using a Hypergeometric model  
14 using GOstats package in R was performed for differentially expressed genes. False  
15 discovery rates (FDR) were corrected with the Benjamini-Hochberg procedure. More  
16 detailed information is included in the online supplement.

17  
18 *Western blot:* Whole cell extracts were isolated using SDS-lysis buffer and separated  
19 by SDS gel electrophoresis, as described in the online supplement.

20  
21 *Statistics:* Results are recorded as mean and SEM. Sample sizes were informed by  
22 standard errors obtained from similar assays in prior publications (13, 18) Decisions  
23 on use of parametric or non-parametric tests were based upon results of D'Agostino-  
24 Pearson normality tests. Comparisons were made by paired student t-test and

1 correlations determined by Spearman's test using Prism 6.0 software (GraphPad Inc.).

2 Significance was defined as  $P < 0.05$ .

3

4

5

1 **Results**

2 *Demographic data for macrophage donors.*

3 The demographic features for the COPD-MAP macrophage donors are listed in Table  
4 1. The COPD patients had a significantly greater number of pack years of cigarette  
5 exposure. Sixteen of 42 COPD patients (38.1%) had a history of frequent  
6 exacerbations ( $\geq 2$ /year). Vaccine history was available in 69% and of these 83% of  
7 COPD patients had received a pneumococcal vaccine.

8

9 *COPD AM have selective defects in phagocytosis of opsonized S. pneumoniae.*

10 Both COPD AM and MDM demonstrated reduced intracellular numbers of *S.*  
11 *pneumoniae* compared to healthy controls, irrespective of opsonic conditions (Figure  
12 1A-D). COPD AM (but not MDM) from frequent exacerbators had reduced  
13 intracellular bacteria, irrespective of opsonic conditions (Figure 1A-D). Frequent  
14 exacerbation was set at  $\geq 2$  exacerbations/yr. and as shown in Figure E1 patients with  
15 only one exacerbation did not have a reduction in bacteria uptake, while those with  $\geq 2$   
16 did. Paired analysis of intracellular bacteria numbers, comparing MDM with AM  
17 from the same donor, showed that intracellular *S. pneumoniae* were lower in AM than  
18 MDM in COPD (but not healthy groups,) regardless of opsonic condition or  
19 exacerbation frequency (Figure 1E-F). Opsonization significantly increased numbers  
20 of intracellular bacteria in all MDM groups, but significantly increased numbers only  
21 in healthy, not COPD, AM (Figure 1G-H).

22

23 The number of viable intracellular *S. pneumoniae* is influenced by both phagocytosis  
24 and the rate of early intracellular killing (13). To establish that lower intracellular  
25 viable bacteria in COPD AM were not due to alterations in bactericidal activity, we

1 measured the kinetics of intracellular killing. Opsonization did not alter the rate of  
2 bacterial killing in any macrophages (Figure E2A-D). Opsonization appropriately  
3 increased both the percentage of healthy AM binding bacteria, and also the  
4 number of internalized bacteria binding per macrophage but did not enhance  
5 uptake in COPD (Figure E3). Binding of non-opsonized or opsonized *S. pneumoniae*  
6 was not altered by COPD or exacerbation frequency. Surface expression of Fc $\gamma$   
7 receptors, CD16, CD32 and CD64 were similar in AM/MDM of COPD patients and  
8 controls (Figure E4A-B). Studies have demonstrated a central role for the Exchange  
9 protein activated by cAMP 1 (Epac-1) in the inhibition of Fc- $\gamma$  receptor-mediated  
10 phagocytosis (20). However, AM expression of Epac-1, or of its primary target Rap-1  
11 (21) was unaltered by *S. pneumoniae* challenge or by COPD (Figure E4C-D).  
12 Similarly, there was no difference in expression of Rac1, a Rho-family GTP-  
13 binding protein that regulates lamellipodia formation and membrane ruffling in Fc  
14 receptor-mediated phagocytosis in AM (22).

15

16 Since COPD AM demonstrate a specific defect in opsonic phagocytosis we confirmed  
17 if patient bronchoalveolar lavage fluid (BAL) samples had significant levels of anti-  
18 pneumococcal antibodies. We measured antibodies against the 13 serotypes included  
19 in Prevnar-13, a licensed protein conjugate vaccine, using a sensitive multiplex  
20 immunoassay. Unconcentrated BAL samples had detectable pneumococcal antibodies  
21 to  $2.9 \pm 0.5$  serotypes and 72% of samples had antibody against at least one serotype,  
22 with a range of 0-9 serotypes. Antibodies were most common to serotypes 3 (38%),  
23 serotype 14 (45%) and serotype 19A (45%), see Figure E5. More specifically for the  
24 COPD sample 73% had detectable antibodies to 1 or more serotypes.

25

1 *Decreased opsonic phagocytosis in COPD is associated with bacterial*  
2 *colonisation and correlates with clinical features.*

3 COPD lungs are often colonized with bacteria, most often *H. influenzae* and *S.*  
4 *pneumoniae* (23), and colonization is associated with increased exacerbation  
5 frequency (6). Since AM are essential mediators of pulmonary innate immunity (24),  
6 we established whether AM phagocytic defects were associated with bacterial  
7 colonization. We found that COPD patients who were culture-positive for pathogenic  
8 micro-organisms (PPMs) in their sputum had significantly lower levels of AM  
9 phagocytosis for opsonized, but not non-opsonized *S. pneumoniae*, when compared to  
10 culture-negative patients (Figure 2A-B). In contrast, using qPCR to identify  
11 pathogenic micro-organisms in BAL, we determined that PCR-positive samples were  
12 not associated with lower levels of opsonic or non-opsonic AM phagocytosis of *S.*  
13 *pneumoniae* (Figure 2C-D).

14  
15 Correlation analysis of non-opsonized and opsonized phagocytosis of *S. pneumoniae*  
16 against FEV<sub>1</sub> showed that there was a significant relationship between FEV<sub>1</sub> and  
17 levels of opsonic phagocytosis, but not non-opsonic phagocytosis (Figure 3A-B).  
18 However, since FEV<sub>1</sub> correlates poorly with symptoms in COPD (25), we also looked  
19 to see if AM phagocytosis levels were related to scores from health-related quality of  
20 life (HR-QoL) instruments, the St George's Respiratory Questionnaire (SGRQ),  
21 COPD Assessment Test (CAT) or with the 6-minute walking distance (6MW). For the  
22 SGRQ and CAT score (although not for the 6MW), there was a significant correlation  
23 between impaired opsonic phagocytosis and scores representative of increased  
24 symptom severity but, in contrast, non-opsonic uptake was not correlated with any

1 HR-QoL score, suggesting it was less tightly associated with COPD symptoms  
2 (Figure 4A-F).  
3 *COPD AM have reduced transcription of antioxidant genes induced in response to*  
4 *opsonized bacteria.*  
5 To provide further insights into the mechanisms influencing the selective defect in  
6 opsonic phagocytosis in AM we next looked at the transcriptional response of AM  
7 to opsonized *S. pneumoniae*. There are significantly fewer differentially expressed  
8 genes in the COPD AM in response to infection than in healthy AM (Figure 5A).  
9 Table E1-2 shows the top ten upregulated and downregulated gene probes in  
10 healthy and COPD AM respectively. We reviewed the enriched GO terms and  
11 noted fewer terms differentially regulated in COPD and lower levels of induction  
12 (Figure 5B). We also observed that, within the Biological Processes differentially  
13 regulated, although the GO term relating to the cellular response to stress was  
14 prominently enriched in healthy AM, it comprised significantly fewer components  
15 in the COPD AM (supplemental Table E3). Included in this response are a series  
16 of genes regulating antioxidant defense, which were prominent in the genes altered  
17 in healthy AM (Figure 5C, supplemental Figure E6 and supplemental Table E4),  
18 but these showed comparatively less differential regulation in in COPD.  
19 Although these responses are not recognized as a major feature of innate host  
20 responses to bacteria, antioxidant responses modulate inflammatory responses.  
21 These antioxidant responses are activated by a variety of sources of oxidative  
22 stress including microbicidal responses to bacteria and baseline reductions in  
23 antioxidant responses are previously described in COPD (26).  
24

1 *Activation of Nrf2 increases phagocytosis of non-opsonized and opsonized S.*  
2 *pneumoniae in AM but not MDM.*

3 Increased oxidative stress in the COPD lung has been associated with impairment  
4 of phagocytosis of non-opsonized unencapsulated bacteria and apoptotic bodies  
5 (27, 28). The transcription factor Nrf2 is a key regulator of cytoprotective proteins  
6 including antioxidants (29, 30) and treatment of macrophages with a pharmacological  
7 activator of Nrf2, sulforaphane, increases phagocytosis of non-type able *H. influenzae*  
8 (NTHi) and *Pseudomonas aeruginosa* in COPD AM (8). Within the differentially  
9 expressed genes in AM following pneumococcal challenge, we identified multiple  
10 Nrf2 regulated genes in healthy AM, but these were not differentially regulated in  
11 COPD AM (Figure 5C and supplemental Table E5).

12  
13 Since we identified impairment of an antioxidant transcriptional module we next  
14 tested whether sulforaphane modulated phagocytosis of *S. pneumoniae*. We  
15 confirmed sulforaphane activated heme-oxygenase (HO-1), an Nrf-2 target gene, in  
16 COPD macrophages (Figure 6A-B) and did not induce either apoptosis or necrosis  
17 in macrophages (Figure E7). Sulforaphane significantly increased numbers of  
18 intracellular bacteria after challenge with non-opsonized *S. pneumoniae* in both  
19 healthy and COPD AM (Figure 6C), but after challenge with opsonized *S.*  
20 *pneumoniae* only in COPD (not healthy) AM (Figure 6D). In contrast, we failed to  
21 demonstrate an uplift in MDM ingestion under any of the conditions studied  
22 (Figure 6E-F). To determine if this pattern occurred with other bacteria, we  
23 confirmed sulforaphane also increased intracellular numbers of NTHi in COPD  
24 AM but not healthy AM/MDM or COPD MDM (Figure 6G-H). We also confirmed  
25 sulforaphane did not alter the rate of early intracellular killing of *S. pneumoniae* in

1 COPD AM (Figure 6I). Moreover, sulforaphane did not significantly induce  
2 expression of Fc-gamma expression (CD16, 32 or 64) in either AM or MDM  
3 (Figure E8). To determine if the uplift in phagocytosis was sulforaphane specific,  
4 cells were also treated with a more specific Nrf2 agonist, Compound 7. This is a  
5 recently described potent and selective inhibitor of the Kelch-like ECH-associated  
6 protein 1 (KEAP1) /Nrf-2 protein-protein interaction (16). Treatment with  
7 Compound 7, also induced expression of HO-1 in COPD MDM in a  
8 concentration-dependent manner (Figure 7A) and also in AM (Figure 7B).  
9 Compound 7 significantly increased phagocytosis of opsonized and non-opsonized  
10 *S. pneumoniae* by AM (Figure 7C-D). COPD MDM treated with Compound 7 also  
11 showed significant increases in uptake of opsonized bacteria and non-opsonized  
12 bacteria, although increased (Figure 7E-F). Compound 7 did not enhance uptake  
13 by healthy macrophages in any condition. As with sulforaphane Compound 7  
14 treatment did not induce cytotoxic effects (Figure E7B). These findings illustrate  
15 the potential to reverse opsonic phagocytic defects with Nrf2 agonists.

16

## 17 **Discussion**

18 We have demonstrated that COPD macrophages have reduced phagocytosis of  
19 bacteria. Although we observed defects in MDM phagocytic function, failure to  
20 induce phagocytic uplift by opsonization was unique to COPD AM and was the  
21 specific defect that was most predictive of clinical phenotype. COPD AM exposed to  
22 opsonized bacteria had decreased transcriptional responses involving antioxidant  
23 defenses. Importantly AM defects in bacterial uptake were reversed with Nrf2  
24 agonists.

25

1 Several prior publications have demonstrated COPD is associated with impaired  
2 macrophage phagocytosis of bacteria and apoptotic cells (8, 9, 10, 31). These studies  
3 suggest that there is both a local AM defect but also a systemic defect in macrophage  
4 function, which may arise from a combination of genetic, epigenetic and  
5 environmental factors. Our study extends our understanding by showing an additional  
6 select defect in AM function that inhibits phagocytosis of opsonized bacteria.

7

8 Both complement and immunoglobulin are present in alveolar lining fluid (14).  
9 Pneumococcal-specific IgG is detected in human BAL (32) and is required for  
10 optimal phagocytosis of *S. pneumoniae* by AM (13). Our study also confirms the  
11 presence of anti-pneumococcal antibodies in unconcentrated BAL, in a COPD  
12 population, in which available data showed >80% vaccination uptake, and an age  
13 matched population some of whom would have had vaccine on the basis of age.  
14 Therefore, a defect in opsonic uptake could reduce the efficacy of vaccination despite  
15 the presence of pneumococcal antibodies in the airway. In a murine model cigarette  
16 smoke reduced complement-mediated *S. pneumoniae* uptake, but not phagocytosis of  
17 IgG coated beads (33). Impaired phagocytosis of opsonized *S. pneumoniae* and other  
18 encapsulated bacteria is likely to contribute to COPD pathogenesis. *S. pneumoniae*  
19 remains a leading cause of exacerbations in COPD (5) and in one study monoculture  
20 of *S. pneumoniae* proved a specific risk factor for exacerbation (17). *S. pneumoniae*  
21 also have indirect effects on exacerbations since they promote growth, biofilm  
22 formation and synergy in inflammatory responses with other bacteria causing  
23 exacerbations (34-36). In addition, *S. pneumoniae* is the major cause of CAP in these  
24 patients (37), and COPD increases the susceptibility and risk of complications with  
25 CAP (7).

1  
2 Recent observations involving polymeric immunoglobulin receptor deficient mice  
3 illustrate how bacterial persistence drives inflammation and small airway remodelling  
4 in a model of COPD (38). Bacterial colonization of the airways is linked to decline in  
5 lung function (6, 39) and recently, bacterial phagocytosis has been shown to correlate  
6 with FEV<sub>1</sub> in both COPD (40) and severe asthma (41). Reduced phagocytosis of  
7 opsonized bacteria by AM was observed in patients who were culture-positive,  
8 although PCR-positivity in BAL was not associated with the level of phagocytosis. It  
9 would be of interest in the future to determine if opsonic phagocytosis correlates with  
10 quantitation of PCR but our numbers did not allow this analysis. We used a threshold  
11 of >10<sup>4</sup> copies/ml to define positivity. Although this threshold ensures sensitivity and  
12 a high negative predictive value in studies on the detection of lower respiratory tract  
13 infection due to organisms such as *S. pneumoniae* and *H. influenzae* (42, 43) it may  
14 underestimate colonization. On the other hand, the detection of colonization by PCR  
15 with lower level PCR thresholds is problematic and diagnostic accuracy may be  
16 influenced by increasing numbers of false positive results. Therefore, the sputum  
17 detection may have been more predictive of colonization status. The defect in AM  
18 phagocytosis of opsonized bacteria was more severe in COPD patients with frequent  
19 exacerbations, a factor associated with more rapid decline in FEV<sub>1</sub> (44). This could  
20 explain the correlations we observed with more significant impairment of opsonic  
21 phagocytosis observed in patients with lower FEV<sub>1</sub> or more severe symptoms with  
22 quality of life assessments. Assessment scales are widely used to describe COPD  
23 patient cohorts and stratify them for interventions, such as pulmonary rehabilitation  
24 (45) and to predict survival (46). Quality of life scales are complementary to FEV<sub>1</sub> in  
25 describing disability (e.g. MRC dyspnea scale) or severity of dyspnea symptoms (e.g.

1 COPD assessment test) in patients living with COPD and it was noteworthy that the  
2 SGRQ and CAT correlated with the defect for phagocytosis of opsonized bacteria.  
3 FEV<sub>1</sub> provides a measure of COPD stage, but correlates poorly with symptoms (25).  
4 This implies the phagocytic defect may be related both to stage and symptoms.  
5  
6 Future studies will need to identify if the phagocytic defect for opsonized bacteria is  
7 related to a specific receptor pathway or cytoskeletal re-arrangement. A prior study  
8 identified a defect in macrophage receptor with collagenous structure (MARCO)  
9 mediated phagocytosis in COPD (8). This important study identified impaired  
10 phagocytosis of two non-opsonized bacteria (NTHi and *P. aeruginosa*) in COPD AM  
11 and mice exposed to cigarette smoke and showed that sulforaphane corrected the  
12 defect in an Nrf2-dependent mechanism via enhanced MARCO expression. Our study  
13 in a population with very few current smokers is consistent with these findings  
14 confirming a defect in phagocytosis of non-opsonized bacteria (*S. pneumoniae* and  
15 NTHi), which is improved by Nrf2 agonists. We extend beyond this showing an  
16 additional defect for opsonized *S. pneumoniae*. In contrast to the study by Harvey and  
17 colleagues our study highlighted transcriptional changes associated with infection in  
18 healthy and COPD AM rather than the transcriptional effects of sulforaphane, but also  
19 highlights reductions in Nrf2-mediated responses in COPD AM. The range of  
20 particles, including both opsonized and non-opsonized bacteria and apoptotic bodies,  
21 for which defects have been identified in COPD, argues against involvement of any  
22 single receptor system underlying all these defects. Although MARCO likely  
23 contributes to defects in uptake of non-opsonized bacteria (8), it would not be  
24 anticipated to explain the impairment of opsonized bacteria by AM. An unbiased  
25 approach is more likely to identify mechanisms underpinning the broad systemic

1 defect in phagocytosis and the more localized pulmonary defect for opsonized  
2 bacteria.

3

4 The transcriptional responses seen in the healthy AM, in response to *S. pneumoniae*  
5 included prominent transcriptional responses involving immunometabolism. The  
6 acute responses to bacteria results in a shift to increased glucose uptake and glycolytic  
7 metabolism (47), while glucose diversion via the pentose phosphate pathway is a  
8 well-recognized mechanism of oxidative stress resistance (48). Amongst differentially  
9 expressed metabolic genes increased in healthy but not COPD AM was sirtuin (silent  
10 mating type information regulation 2 homologs) 1, a deacetylase involved in host  
11 responses to *M. tuberculosis* (49). Anti-oxidant responses were prominently  
12 upregulated in healthy AM after bacterial infection. Nrf2 regulated genes included  
13 glutamate-cysteine ligase catalytic subunit (GCLC), glutathione-S-transferase zeta 1  
14 (GSTZ-1), glutathione peroxidase 7 (GPX7) and the SLC7A11 gene product, light  
15 chain subunit of the Xc<sup>-</sup> (xCT) glutamine/cysteine antiporter required, all involved in  
16 glutathione maintenance and utilization, carbonyl reductase 1 (CBR1),  
17 NADPH:quinone oxidoreductase 1 (NQO1), and thioredoxin 2 (TXN2) detoxifying  
18 oxidoreductase enzymes and superoxide dismutase (SOD) 1 (48). Foxo-regulated  
19 targets including SOD 2 were upregulated, while p53 was also upregulated. Of all  
20 these anti-oxidant responses only p53 was significantly upregulated in COPD AM  
21 after bacterial challenge. We identified upregulation of a series of genes involved in  
22 regulation of ubiquitination (including ubiquitin conjugating E2 enzymes B, D3 and  
23 N), a process controlling signaling via pattern recognition receptors, in healthy AM  
24 after bacterial challenge (50). Collectively these anti-oxidant responses have the  
25 potential to alter cytokine-induced activation of specific phagocytic pathways,

1 expression of receptors or molecules involved in signaling cascades associated with  
2 receptors or the susceptibility of the cytoskeleton to re-arrangements altered by  
3 oxidative stress required for particular phagocytic pathways. It was noteworthy that  
4 the transcriptional response in healthy AM involved downregulation of the class B  
5 scavenger receptor CD36, a receptor for unopsonized particles (51) , which was not  
6 observed in COPD AM.

7

8 The Nrf2 transcription factor regulates a cluster of antioxidant, cytoprotective and  
9 detoxifying genes and influences susceptibility to COPD in murine models involving  
10 cigarette smoke exposure by modifying inflammation and tissue injury (52). We  
11 confirmed prior observations suggesting Nrf2 agonists correct the phagocytic defect  
12 in COPD (8), but extend these by showing they also modulate phagocytosis of  
13 opsonized bacteria. Since this also influenced uptake of non-opsonized particles it is  
14 likely Nrf2 agonists have pleiotropic effects in the modulation of phagocytosis. Nrf2  
15 agonists represent a promising class of agents with which to modulate oxidative stress  
16 in conditions like COPD, particularly with the development of highly-selective agents  
17 that bind to the Kelch domain of KEAP1 and prevent Nrf2 ubiquitination and  
18 proteasomal degradation (16). While sulforaphane activates Nrf2 by targeting  
19 cysteine residues in the BTB domain of KEAP1 and can potentially interact with  
20 other targets (53) we demonstrate significant enhancement of phagocytosis in COPD  
21 macrophages with the selective Nrf2 agonist Compound 7, suggesting this could  
22 represent a potent pharmacological approach with which to correct the COPD  
23 associated defects in phagocytosis.

24

25 In conclusion we have identified that, although COPD induces a systemic defect in a

1 range of forms of phagocytosis, a specific defect in phagocytosis of opsonized  
2 bacteria is observed specifically in AM and correlates closely with clinical phenotype  
3 in COPD. Moreover, this defect is amenable to therapeutic targeting with novel and  
4 selective inhibitors of the KEAP1/Nrf2 protein-protein interaction.

5

6

7 **Acknowledgements.**

8 We would like to thank Prof. Ian Sabroe in setting up ethics approvals for research  
9 bronchoscopies and in for discussions on pulmonary host defense. This report is  
10 independent research supported by National Institute for Health Research (NIHR)  
11 South Manchester Respiratory and Allergy Clinical Research Facility at University  
12 Hospital of South Manchester NHS Foundation Trust and the NIHR Clinical Research  
13 Facility at Sheffield Teaching Hospitals Foundation Trust. The views expressed in  
14 this publication are those of the author(s) and not necessarily those of the NHS, the  
15 National Institute for Health Research or the Department of Health.

1 **Figure Legends**

2

3 **Figure 1. COPD AM show deficient opsonic bacterial phagocytosis which**

4 **correlates with exacerbation frequency. (A-D)** Alveolar macrophages (AM) (A

5 and B) or monocyte-derived macrophages (MDM) (C and D) from healthy (H) or

6 COPD (non-frequent (NF) and frequent (F) exacerbators) were challenged with either

7 non-opsonized (A and C) or opsonized (B and D) serotype 14 *S. pneumoniae*. 4h post-

8 challenge *viable* intracellular bacteria were assessed. Values for 'n=' for H/COPD-

9 NF/COPD-F; (A) 18/27/15, (B) 10/19/13, (C) 14/18/12, (D) 14/15/12, \*\*\*= p<0.001,

10 1-way ANOVA. **(E-F)** A pairwise comparison of phagocytosis of non-opsonized (E)

11 and opsonized (F) bacteria in MDM and AM from matched donors, ns= not

12 significant, values for 'n=' for H/COPD-NF/COPD-F; (E) 11/12/12, (F) 10/11/12,

13 \*=p<0.05, \*\*=p<0.01, \*\*\*=p<0.001, paired t-test. **(G-H)** A pairwise comparison of

14 phagocytosis of non-opsonized and opsonized *S. pneumoniae* in matched AM (G) or

15 MDM (H) donors, values for 'n=' for H/COPD-NF/COPD-F; (G) 10/20/11, (H) 7/8/5,

16 \*=p<0.05, paired t-test.

17

18 **Figure 2. Defects in phagocytosis in COPD AM are associated with bacterial**

19 **colonisation in the lung. (A-D)** Non-opsonic (A and C) and opsonic (B and D)

20 phagocytosis was stratified into groups dependent on if the donor had negative (-ve)

21 or positive (+ve) culture of sputum (A and B, n=15 and n=14) or -ve or +ve (defined

22 as >10<sup>4</sup> copies/ml) qPCR of broncho-alveolar lavage (C and D, n=27 and n=26)

23 results indicative of bacterial colonisation, \*=p<0.05, Student's t-test.

24

1 **Figure 3. Opsonic phagocytosis correlates with FEV<sub>1</sub>.** Non-opsonic (A) and  
2 opsonic (B) phagocytosis rates were correlated against patient FEV<sub>1</sub> score. Pearson's  
3 correlation coefficients (r), and p values, with correlation deemed significant if  
4 p<0.05. n = 36 non-opsonic, 32 opsonic.

5

6 **Figure 4. Opsonic phagocytosis correlates with markers of COPD disease**  
7 **severity.** Non-opsonic (A, C and E) and opsonic (B, D and F) rates of phagocytosis  
8 were correlated against patients scores in a variety of markers for COPD disease  
9 severity, the St George's Respiratory Questionnaire (SGRQ) (A and B) (n = 29 non-  
10 opsonic, 27 opsonic), COPD Assessment Test (CAT) (C and D) (n = 34 non-opsonic,  
11 30 opsonic) or with the 6-minute walking distance (6MW) (E and F) (n = 14 non-  
12 opsonic, 10 opsonic). Values for Pearson's (r) or Spearman's correlation coefficients  
13 (rho) and p values are shown, with correlation deemed significant if p= <0.05.

14

15 **Figure 5. Transcriptional response of AM reveals less differential gene**  
16 **expression in COPD in response to infection.** Alveolar macrophages (AM) from  
17 Healthy or COPD patients were challenged with opsonized serotype 14 *S.*  
18 *pneumoniae* (n=3 in each group). 4h post-challenge cell total RNA was collected for  
19 transcriptional analysis. (A) Venn diagram showing the number of probes  
20 differentially expressed in response to infection (moderated t test <0.05, FDR <0.05).  
21 (B) Plots represent the top ten enriched GO biological processes terms and the cellular  
22 response to stress term (in addition the response to oxidative stress term is plotted in  
23 the Healthy AM). The X axis represents enrichment by a hypergeometric test (-log<sub>10</sub>  
24 (p value)). The size of the circle and colour represents the number of differentially  
25 expressed genes in that term. Figures generated using NIPA (available

1 at <https://github.com/ADAC-UoN/NIPA>). (C) Volcano plots represent the probe sets  
2 identified from the transcriptomic analysis. Panel a) Healthy: The red triangles are the  
3 differentially expressed probes related to the “Cellular response to stress term” with  
4 some representative terms named. In blue are the terms associated with the Nrf-2  
5 pathway in the analysis of healthy AM. Panel b) COPD: The red triangles are the  
6 differentially expressed probes related to the “Cellular response to stress” GO term. In  
7 blue are the terms associated with NRF2 pathway seen in the Healthy analysis.

8

9 **Figure 6. Treatment with the Nrf-2 agonist sulforaphane increases non-opsonic**  
10 **and opsonic phagocytosis in COPD AM but not MDM. (A-B)** Alveolar  
11 macrophages (AM) and monocyte derived macrophages (MDM)(B) were pre-treated  
12 with the designated dose of sulforaphane (Sulf) for 16h, before cells were lysed and  
13 probed for expression of heme-oxygenase-1 (HO-1) and actin (n=3). (C-F) AM (C-D)  
14 or MDM (E and F) from healthy (H) or COPD non-frequent (NF) or frequent (F)  
15 exacerbators were pre-treated with vehicle (Sulf -) or Sulforaphane (Sulf +) for 16 h,  
16 before cells were challenged with non-opsonized (C and E) or opsonized (D and F)  
17 serotype 14 *S. pneumoniae*. 4h post-challenge, numbers of intracellular viable bacteria  
18 were measured, values for ‘n=’ for H/COPD-NF/COPD-F; (C) 11/19/14, (D) 8/ 10/4,  
19 (E) 9/9/5, (F) 8/9/5, \*=p<0.05, paired t-test. (G and H) AM (G) and MDM (H) from  
20 COPD patients or healthy (H) (red lines) donors were pre-treated with sulforaphane  
21 before being challenged with non-typeable *H. influenzae* (NTHi). 4h post challenge  
22 the numbers of intracellular viable bacteria were measured, values for ‘n=’ for  
23 H/COPD (G)3/4, (H) 2/3, \*=p<0.05, paired t-test. (I) COPD AM were pre-treated  
24 with sulforaphane (+Sulf) before being challenged with non-opsonized serotype 14 *S.*  
25 *pneumoniae* for 4h before extracellular bacteria were killed by the addition of

1 antibiotics. At the designated time post-antibiotics, viable bacteria in duplicate wells  
2 were measured to, n=3, no significant difference between vehicle and sulf.

3

4 **Figure 7. The Nrf-2 agonist compound 7 also increases phagocytosis in COPD**  
5 **AM.**

6 **(A and B)** COPD monocyte-derived macrophages (MDM) (A), or alveolar  
7 macrophages (AM) (B), were pre-treated with the Nrf-2 agonist Compound 7 for 16h  
8 at the designated dose, before cells were lysed and a probed for the expression of  
9 heme-oxygenase-1 (HO-1) by western blot. **(C and D)** Healthy donor and COPD AM  
10 were pre-treated with Compound 7 at 5x IC<sub>50</sub> (0.065 μM), for 16h before being  
11 challenged with opsonized (C), n=3 healthy, n=5 COPD or non-opsonized (D), n=1  
12 healthy, n=10 COPD, serotype 14 *S. pneumoniae* for 4h, after which numbers of  
13 intracellular viable bacteria were assessed, \*\*=p<0.01, paired t-test. **(E and F)**  
14 Healthy donor and COPD MDM were pre-treated with compound 7 and challenged  
15 with opsonized (E), or non-opsonized (F), *S. pneumoniae* as for AM. All n=4, p  
16 \*\*=p<0.01, paired t-test.

17

18

## 19 **References**

20

- 21 1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM.  
22 Global burden of copd: Systematic review and meta-analysis. *The European*  
23 *respiratory journal* 2006;28:523-532.
- 24 2. Barnes PJ. Alveolar macrophages in chronic obstructive pulmonary disease  
25 (copd). *Cellular and molecular biology* 2004;50 Online Pub:OL627-637.
- 26 3. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R,  
27 Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF,  
28 Wedzicha JA. Susceptibility to exacerbation in chronic obstructive pulmonary  
29 disease. *The New England journal of medicine* 2010;363:1128-1138.
- 30 4. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha  
31 JA. Effect of exacerbation on quality of life in patients with chronic obstructive

- 1 pulmonary disease. *American journal of respiratory and critical care medicine*  
2 1998;157:1418-1422.
- 3 5. Sapey E, Stockley RA. Copd exacerbations . 2: Aetiology. *Thorax*  
4 2006;61:250-258.
- 5 6. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha  
6 JA. Relationship between bacterial colonisation and the frequency, character, and  
7 severity of copd exacerbations. *Thorax* 2002;57:759-764.
- 8 7. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. Copd is associated with  
9 increased mortality in patients with community-acquired pneumonia. *Eur Respir J*  
10 2006;28:346-351.
- 11 8. Harvey CJ, Thimmulappa RK, Sethi S, Kong X, Yarmus L, Brown RH, Feller-  
12 Kopman D, Wise R, Biswal S. Targeting nrf2 signaling improves bacterial clearance  
13 by alveolar macrophages in patients with copd and in a mouse model. *Science*  
14 *translational medicine* 2011;3:78ra32.
- 15 9. Berenson CS, Wrona CT, Grove LJ, Maloney J, Garlipp MA, Wallace PK,  
16 Stewart CC, Sethi S. Impaired alveolar macrophage response to haemophilus antigens  
17 in chronic obstructive lung disease. *American journal of respiratory and critical care*  
18 *medicine* 2006;174:31-40.
- 19 10. Taylor AE, Finney-Hayward TK, Quint JK, Thomas CM, Tudhope SJ,  
20 Wedzicha JA, Barnes PJ, Donnelly LE. Defective macrophage phagocytosis of  
21 bacteria in copd. *The European respiratory journal* 2010;35:1039-1047.
- 22 11. Palecanda A, Kobzik L. Receptors for unopsonized particles: The role of  
23 alveolar macrophage scavenger receptors. *Current molecular medicine* 2001;1:589-  
24 595.
- 25 12. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages.  
26 *Annual review of immunology* 1999;17:593-623.
- 27 13. Gordon SB, Irving GR, Lawson RA, Lee ME, Read RC. Intracellular  
28 trafficking and killing of streptococcus pneumoniae by human alveolar macrophages  
29 are influenced by opsonins. *Infection and immunity* 2000;68:2286-2293.
- 30 14. Nicod LP. Lung defences: An overview. *European Respiratory Review*  
31 2005;14:45-50.
- 32 15. Bewley MA. Copd alveolar macrophages have a defect in opsonic  
33 phagocytosis of serotype 14 streptococcus pneumoniae. . 2014;189.
- 34 16. Davies TG, Wixted WE, Coyle JE, Griffiths-Jones C, Hearn K, McMenamin  
35 R, Norton D, Rich SJ, Richardson C, Saxty G, Willems HM, Woolford AJ, Cottom  
36 JE, Kou JP, Yonchuk JG, Feldser HG, Sanchez Y, Foley JP, Bolognese BJ, Logan G,  
37 Podolin PL, Yan H, Callahan JF, Heightman TD, Kerns JK. Monoacidic inhibitors of  
38 the kelch-like ech-associated protein 1: Nuclear factor erythroid 2-related factor 2  
39 (keap1:Nrf2) protein-protein interaction with high cell potency identified by  
40 fragment-based discovery. *Journal of medicinal chemistry* 2016;59:3991-4006.
- 41 17. Bogaert D, van der Valk P, Ramdin R, Sluijter M, Monninkhof E, Hendrix R,  
42 de Groot R, Hermans PW. Host-pathogen interaction during pneumococcal infection  
43 in patients with chronic obstructive pulmonary disease. *Infect Immun* 2004;72:818-  
44 823.
- 45 18. Dockrell DH, Lee M, Lynch DH, Read RC. Immune-mediated phagocytosis  
46 and killing of streptococcus pneumoniae are associated with direct and bystander  
47 macrophage apoptosis. *The Journal of infectious diseases* 2001;184:713-722.
- 48 19. Marriott HM, Ali F, Read RC, Mitchell TJ, Whyte MK, Dockrell DH. Nitric  
49 oxide levels regulate macrophage commitment to apoptosis or necrosis during

- 1 pneumococcal infection. *FASEB journal : official publication of the Federation of*  
2 *American Societies for Experimental Biology* 2004;18:1126-1128.
- 3 20. Aronoff DM, Canetti C, Serezani CH, Luo M, Peters-Golden M. Cutting edge:  
4 Macrophage inhibition by cyclic amp (camp): Differential roles of protein kinase a  
5 and exchange protein directly activated by camp-1. *Journal of immunology*  
6 2005;174:595-599.
- 7 21. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer  
8 A, Bos JL. Epac is a rap1 guanine-nucleotide-exchange factor directly activated by  
9 cyclic amp. *Nature* 1998;396:474-477.
- 10 22. Castellano F, Montcourrier P, Chavrier P. Membrane recruitment of rac1  
11 triggers phagocytosis. *Journal of cell science* 2000;113 ( Pt 17):2955-2961.
- 12 23. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary  
13 disease. *Respir Care* 2003;48:1204-1213; discussion 1213-1205.
- 14 24. Dockrell DH, Whyte MK, Mitchell TJ. Pneumococcal pneumonia:  
15 Mechanisms of infection and resolution. *Chest* 2012;142:482-491.
- 16 25. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA,  
17 MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates  
18 JC, Vestbo J. Characterisation of copd heterogeneity in the eclipse cohort. *Respiratory*  
19 *research* 2010;11:122.
- 20 26. Tudor RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease.  
21 *J Clin Invest* 2012;122:2749-2755.
- 22 27. Marti-Llitas P, Regueiro V, Morey P, Hood DW, Saus C, Sauleda J, Agusti  
23 AG, Bengoechea JA, Garmendia J. Nontypeable haemophilus influenzae clearance by  
24 alveolar macrophages is impaired by exposure to cigarette smoke. *Infection and*  
25 *immunity* 2009;77:4232-4242.
- 26 28. Richens TR, Linderman DJ, Horstmann SA, Lambert C, Xiao YQ, Keith RL,  
27 Boe DM, Morimoto K, Bowler RP, Day BJ, Janssen WJ, Henson PM, Vandivier RW.  
28 Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent  
29 activation of rhoa. *American journal of respiratory and critical care medicine*  
30 2009;179:1011-1021.
- 31 29. Goven D, Boutten A, Lecon-Malas V, Marchal-Somme J, Amara N, Crestani  
32 B, Fournier M, Leseche G, Soler P, Boczkowski J, Bonay M. Altered nrf2/keap1-  
33 bach1 equilibrium in pulmonary emphysema. *Thorax* 2008;63:916-924.
- 34 30. Zhao H, Eguchi S, Alam A, Ma D. The role of nuclear factor-erythroid 2  
35 related factor 2 (nrf-2) in the protection against lung injury. *American journal of*  
36 *physiology Lung cellular and molecular physiology* 2017;312:L155-L162.
- 37 31. Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M. Alveolar  
38 macrophages from subjects with chronic obstructive pulmonary disease are deficient  
39 in their ability to phagocytose apoptotic airway epithelial cells. *Immunol Cell Biol*  
40 2003;81:289-296.
- 41 32. Eagan R, Twigg HL, 3rd, French N, Musaya J, Day RB, Zijlstra EE, Tolmie  
42 H, Wyler D, Molyneux ME, Gordon SB. Lung fluid immunoglobulin from hiv-  
43 infected subjects has impaired opsonic function against pneumococci. *Clin Infect Dis*  
44 2007;44:1632-1638.
- 45 33. Phipps JC, Aronoff DM, Curtis JL, Goel D, O'Brien E, Mancuso P. Cigarette  
46 smoke exposure impairs pulmonary bacterial clearance and alveolar macrophage  
47 complement-mediated phagocytosis of streptococcus pneumoniae. *Infection and*  
48 *immunity* 2010;78:1214-1220.
- 49 34. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. Viral and  
50 bacterial interactions in the upper respiratory tract. *PLoS Pathog* 2013;9:e1003057.

- 1 35. Ratner AJ, Aguilar JL, Shchepetov M, Lysenko ES, Weiser JN. Nod1  
2 mediates cytoplasmic sensing of combinations of extracellular bacteria. *Cell*  
3 *Microbiol* 2007;9:1343-1351.
- 4 36. Tikhomirova A, Kidd SP. Haemophilus influenzae and streptococcus  
5 pneumoniae: Living together in a biofilm. *Pathog Dis* 2013;69:114-126.
- 6 37. Torres A, Dorca J, Zalacain R, Bello S, El-Ebiary M, Molinos L, Arevalo M,  
7 Blanquer J, Celis R, Iriberry M, Prats E, Fernandez R, Irigaray R, Serra J.  
8 Community-acquired pneumonia in chronic obstructive pulmonary disease: A spanish  
9 multicenter study. *Am J Respir Crit Care Med* 1996;154:1456-1461.
- 10 38. Richmond BW, Brucker RM, Han W, Du RH, Zhang Y, Cheng DS, Gleaves  
11 L, Abdolrasulnia R, Polosukhina D, Clark PE, Bordenstein SR, Blackwell TS,  
12 Polosukhin VV. Airway bacteria drive a progressive copd-like phenotype in mice  
13 with polymeric immunoglobulin receptor deficiency. *Nat Commun* 2016;7:11240.
- 14 39. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between  
15 airway bacterial load and markers of airway inflammation in patients with stable  
16 chronic bronchitis. *The American journal of medicine* 2000;109:288-295.
- 17 40. Berenson CS, Kruzel RL, Eberhardt E, Sethi S. Phagocytic dysfunction of  
18 human alveolar macrophages and severity of chronic obstructive pulmonary disease.  
19 *The Journal of infectious diseases* 2013;208:2036-2045.
- 20 41. Liang Z, Zhang Q, Thomas CM, Chana KK, Gibeon D, Barnes PJ, Chung KF,  
21 Bhavsar PK, Donnelly LE. Impaired macrophage phagocytosis of bacteria in severe  
22 asthma. *Respiratory research* 2014;15:72.
- 23 42. Blaschke AJ. Interpreting assays for the detection of streptococcus  
24 pneumoniae. *Clin Infect Dis* 2011;52 Suppl 4:S331-337.
- 25 43. Abdeldaim GM, Stralin K, Korsgaard J, Blomberg J, Welinder-Olsson C,  
26 Herrmann B. Multiplex quantitative pcr for detection of lower respiratory tract  
27 infection and meningitis caused by streptococcus pneumoniae, haemophilus  
28 influenzae and neisseria meningitidis. *BMC Microbiol* 2010;10:310.
- 29 44. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship  
30 between exacerbation frequency and lung function decline in chronic obstructive  
31 pulmonary disease. *Thorax* 2002;57:847-852.
- 32 45. Wedzicha JA, Bestall JC, Garrod R, Garnham R, Paul EA, Jones PW.  
33 Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive  
34 pulmonary disease patients, stratified with the mrc dyspnoea scale. *The European*  
35 *respiratory journal* 1998;12:363-369.
- 36 46. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-  
37 year survival than airway obstruction in patients with copd. *Chest* 2002;121:1434-  
38 1440.
- 39 47. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick  
40 AF, Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, Zheng L, Gardet A, Tong Z,  
41 Jany SS, Corr SC, Haneklaus M, Caffrey BE, Pierce K, Walmsley S, Beasley FC,  
42 Cummins E, Nizet V, Whyte M, Taylor CT, Lin H, Masters SL, Gottlieb E, Kelly VP,  
43 Clish C, Auron PE, Xavier RJ, O'Neill LA. Succinate is an inflammatory signal that  
44 induces il-1beta through hif-1alpha. *Nature* 2013;496:238-242.
- 45 48. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer  
46 strategy. *Nat Rev Drug Discov* 2013;12:931-947.
- 47 49. Cheng CY, Gutierrez NM, Marzuki MB, Lu X, Foreman TW, Paleja B, Lee B,  
48 Balachander A, Chen J, Tsenova L, Kurepina N, Teng KWW, West K, Mehra S,  
49 Zolezzi F, Poidinger M, Kreiswirth B, Kaushal D, Kornfeld H, Newell EW, Singhal

1 A. Host sirtuin 1 regulates mycobacterial immunopathogenesis and represents a  
2 therapeutic target against tuberculosis. *Sci Immunol* 2017;2.  
3 50. Zinngrebe J, Montinaro A, Peltzer N, Walczak H. Ubiquitin in the immune  
4 system. *EMBO Rep* 2014;15:28-45.  
5 51. Febbraio M, Hajjar DP, Silverstein RL. Cd36: A class b scavenger receptor  
6 involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. *J Clin*  
7 *Invest* 2001;108:785-791.  
8 52. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW,  
9 Yamamoto M, Petrache I, Tuder RM, Biswal S. Genetic ablation of nrf2 enhances  
10 susceptibility to cigarette smoke-induced emphysema in mice. *J Clin Invest*  
11 2004;114:1248-1259.  
12 53. Hu C, Eggler AL, Mesecar AD, van Breemen RB. Modification of keap1  
13 cysteine residues by sulforaphane. *Chem Res Toxicol* 2011;24:515-521.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46



1

2

3 **Table 1: Demographics of Macrophage Donors**

	Healthy Non-Smoker	Healthy Ex-Smoker	COPD
<b>N</b>	12	6	42
<b>Age (years)</b>	56 (43-65)	58 (48-69)	66(53-77)
<b>Gender</b>	6♀ : 6♂	2♀ : 4♂	7♀ : 35♂
<b>FEV1 Litres</b>	3.19 (2.25-4.77)	2.99 (2.50-3.70)	1.88 (1.00-2.72)
<b>FEV1 %</b>	110 (74-127)	108 (84-121)	50.8 (32-67)
<b>FVC litres</b>	3.76 (2.25-5.6)	4.19 (3.45-5.2)	3.49 (1.86-5.24)
<b>GOLD Stage *</b>	N/A	N/A	9 GOLD A 14 GOLD B 4 GOLD C 10 GOLD D
<b>Non-Frequent /Frequent**</b>	N/A	N/A	NF 26 (0 Exacerbations = 19, 1 Exacerbation = 7 F 16 (2 Exacerbations =3, 3 Exacerbations =7, >3 Exacerbations =6)
<b>Pack Years</b>	N/A	18 (10-35)	50 (32-67)
<b>Smoking Status: Current/Ex/Never</b>	0/0/12	0/6/0	7/35/0
<b>Inhaled Corticosteroids use</b>	0	0	35
<b>Vaccine</b>	N/A	N/A	24 Yes, 5 No, 13N/A
<b>St George's Respiratory Questionnaire (SGRQ) Total score</b>	N/A	N/A	39.8 (6-83)
<b>COPD Assessment Test (CAT)</b>	N/A	N/A	16.3 (4-33)
<b>6 Minute Walk (m)</b>	N/A	N/A	400 (264-496)

4